Abstract:
Introduced 30 years ago, reperfusion therapies have become standard of care in the acute management of ST elevation MI. The criteria for assessing success of these strategies have not kept apace with the refinement of primary PCI systems of care. It is about time these legacy measures shaped by early reperfusion trial criteria are updated to reflect the predominant focus of contemporary clinical practice.
Audience Take Away:
• Revisiting historical criteria for gauging reperfusion success
• Shifting focus to what really matters in the acute treatment of STEMI
• Redefining key performance indicators • Shaping future trial design and endpoints
Biography:
Richard Lim, MBBS(Hons), MD, MPhil, FRCP(Lond), FACC, FESC, Interventional Cardiologist at The Princess AlexandraHospital Brisbane since July 1997 and Associate Professor of Medicine at The University of Queensland, graduated 1984 from The University of Newcastle upon Tyne UK, undertaking cardiology training at St Bartholomew’s Hospital London (1989–94) where he also completed his research MD on prognostic assessment of CAD by nuclear cardiology and research MPhil on outcomes of patients awaiting revascularisation. Further sub-specialty experience at the Royal Hull & East Yorkshire Hospitals led to the CCST(UK 1996), then a sabbatical year as Post-Doctoral Interventional Fellow at the University of Maryland Hospital Baltimore USA. Richard performed the first-ever PCI at the PA Hospital in1998 and maintains a research focus on prognosis in CAD and quality improvement in PCI.
